Loading stock data…
SERA
$1.91-0.03 (-1.55%)
Market ClosedLast close May 1
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sera Prognostics, Inc. in the Healthcare sector is trading at $1.91. The stock is currently near its 52-week low of $1.37, remaining 32.0% below its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why SERA maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.91
Potential Upside
5%
Whystock Fair Value$2.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.34%
Volume
Today's trading volume
22,476
Recent News
Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 Top-Ranked Stocks With Rising P/E That Investors Can Bet On
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are HRB, SPWH, SERA, VEEV and WKHS.
Sera Prognostics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q4 2025 earnings call
Sera Prognostics Inc (SERA) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...
Sera Prognostics Inc (SERA) reports a mixed quarter with declining revenue but strategic advancements in state engagement and European market entry.
Sera Prognostics Q4 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) executives emphasized progress in evidence generation and early commercialization efforts during the company’s fourth-quarter and full-year 2025 earnings call, held March 18, 2026. Management highlighted the publication of its pivotal PRIME study, a growing pipeline of